论文部分内容阅读
支气管哮喘(以下简称哮喘)是一种气道慢性变态反应性疾病,目前吸入疗法已成为哮喘治疗的主要给药方式。哮喘发作期由于支气管平滑肌的痉挛、粘液分泌增加、粘膜肿胀,导致气道阻力增高,通气功能障碍。吸入β_2受体激动剂后数分钟即能产生支气管扩张作用,迅速缓解症状。为了解沙丁胺醇雾化液(商品名:全乐宁)对哮喘的治疗效果。2001年8月~10月,我院采用QW15雾化吸入器吸入沙丁胺醇治疗哮喘患儿30例,观察其吸药前后症状改善、肺部体征及最大呼气峰流速值(PEFR)变化。1 资料与方法 本组患儿均来自哮喘专业门诊,其中男20例,女10例;年龄6~14岁,平均9.37±2,57岁。身高113.0~162.0cm,平均138.3±13.96cm。病程最短
Bronchial asthma (hereinafter referred to as asthma) is an airway chronic allergic disease, inhalation therapy has become the main mode of administration of asthma treatment. Asthma attack due to bronchial smooth muscle spasm, increased mucus secretion, mucosal swelling, leading to increased airway resistance, ventilation dysfunction. Inhaled beta 2 receptor agonist can produce bronchodilation after a few minutes, quickly relieve symptoms. To understand the salbutamol nebulizer (trade name: Quanlein) on the treatment of asthma. From August to October 2001, 30 cases of asthmatic children were inhaled with albuterol QW15 inhalation, and their symptoms, pulmonary signs and maximum expiratory flow velocity (PEFR) were observed before and after drug inhalation. 1 Materials and Methods The children were from asthma clinic, including 20 males and 10 females; aged 6 to 14 years, mean 9.37 ± 2,57 years. Height 113.0 ~ 162.0cm, an average of 138.3 ± 13.96cm. The shortest course